Novo Nordisk enters partnership with Belgian company
Denmark’s Novo Nordisk has entered a collaboration to discover and develop nano-antibodies with a Belgian biotech company. It is not known which disease areas the partnership will target.
BY ELIZABETH MØNSTED JOHANSEN
Belgium-based Ablynx says it has entered a collaboration and licensing deal with Denmark’s Novo Nordisk. The deal pertains to the discovery and development of novel multi-specific Nanobody drug candidates for use in an undisclosed disease area, with an option to expand the agreement to include a second Nanobody program.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo to invest DKK 2 billion and create 450 jobs
For abonnenter
Strong growth in Novo's Southeast Asian organization
For abonnenter
Rebien: Tresiba will not be profitable at first
For abonnenter
